CDMO Activity Tracker: Lupin’s CDMO commissions oncology block in India; Cambrex, Axplora, Hovione expand operations

Data Compilation
#PharmaFlow

Pipeline Prospector November 2025: Kimberly-Clark to buy Kenvue for US$ 48.7 bn; FDA approves Novartis’ gene therapy

Stock Recap
#PipelineProspector

Pixin

ACCESS ALL DATA, CHEMISTRY

ACTIVE PHARMA INGREDIENTS

39 API Suppliers, 11 USDMF, 5 JDMF, 5 EU WC, 15 KDMF, 8 NDC API, 16 Listed Suppliers, $ API Reference Price

DEVELOPMENTS

23 Drugs in Development

23 Drugs in Development

INTERMEDIATES

1 Intermediate Suppliers

1 Intermediate Suppliers

FINISHED DOSAGE FORMULATIONS

135 FDF Dossiers, 27 FDA Orange Book, 59 Europe, 9 Canada, 26 Australia, 6 South Africa, 8 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

TABLET;ORAL - 125MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET;ORAL - 250MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET;ORAL - 500MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

RELATED EXCIPIENT COMPANIES

1 Minakem, 2 SPI Pharma, 12 DKSH, 5 Boai NKY Pharmaceuticals Ltd, 6 Gangwal Healthcare, 5 Nanjing Well Pharmaceutical, 1 Shanghai Minbiotech, 2 Kirsch Pharma, 1 ACG Worldwide, 5 Actylis, 1 Alcedo Pharmachem, 9 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd, 3 Ashland, 28 BASF, 1 Clariant, 10 Corel Pharma Chem, 7 DFE Pharma, 2 Esteem Industries, 1 Finar, 12 Gangwal Chemicals, 4 Ideal Cures, 2 Ingredion Pharma Solutions, 24 Kerry, 3 Keval Exports, 3 Kima Chemical, 6 Lonza Capsugel, 15 Microlex e.U, 2 Nanjing Bold Chemical, 3 Nitika Pharmaceutical Specialities, 2 Nomisma Healthcare, 3 Novo Excipients, 5 Pharmatrans-Sanaq, 4 Pluviaendo, 4 Prachin Chemical, 1 Qianhao Chemical (Hebei) Co., Ltd, 1 Qualicaps, 15 Roquette, 12 Seppic, 4 Shanghai Shenmei Pharmaceutical Technology Co., Ltd, 10 Sigachi Industries, 4 Silverline Chemicals, 2 The Dow Chemical Company, 1 Ulanqab Kema New Material, 4 Vasa Pharmachem

EXCIPIENTS BY APPLICATIONS

52 Fillers, Diluents & Binders, 43 Coating Systems & Additives, 38 Disintegrants & Superdisintegrants, 32 Direct Compression, 31 Granulation, 29 Thickeners and Stabilizers, 28 Solubilizers, 22 Lubricants & Glidants, 21 Controlled & Modified Release, 17 Topical, 14 Film Formers & Plasticizers, 11 Parenteral, 10 Co-Processed Excipients, 10 Chewable & Orodispersible Aids, 9 Emulsifying Agents, 7 Rheology Modifiers, 5 Empty Capsules, 5 API Stability Enhancers, 4 Vegetarian Capsules, 4 Surfactant & Foaming Agents, 4 Taste Masking, 4 Coloring Agents

DIGITAL CONTENT

6 News #PharmaBuzz

6 News #PharmaBuzz

GLOBAL SALES INFORMATION

7 US Medicaid Prescriptions, 39 Regulatory FDF Prices

MARKET PLACE

5 APIs

5 APIs

PATENTS & EXCLUSIVITIES

7 Health Canada Patents

7 Health Canada Patents

REF. STANDARDS & IMPURITIES

11 Others

11 Others

$ Xls download

Filters

Last Updated on PharmaCompass	Virtual Booth	Country	Registrant Name	Registration No.	Compound	Registration Date	Manufacturer	Manufacturer's Country	Manufacturer's Address
29/11/2025	CHANGZHOU KONY PHARMACEUTICAL CO., LTD. CN 213 105 Changzhou	China	Kosha Bio Co., Ltd.	20180208-209-J-153(4)	Palmciclovir	2019-01-24	Changzhou Kony Pharmaceutical Co.,Ltd.	China	Daixi Street, Luoyang Town, Wujin District, Changzhou, Jiangsu China
29/11/2025	Charioteer	China	Sampoong Finechem Co., Ltd.	20210303-209-J-743	Famciclovir	2021-03-03	Zhejiang Charioteer Pharmaceutical Co., Ltd.@Zhejiang Charioteer Pharmaceutical Co., Ltd.	China	Tongyuanxi, Dazhan, Xianju, Zhejiang Province, 317321, PR China@Fengxi West Road No. 5, Modern Industry Zone, Xianju, Zhejiang Province, 317300, PR China

Pixin

Pixin

ACCESS ALL DATA

Browse all information

CHEMISTRY

Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

39 API Suppliers

11 USDMF

5 JDMF

5 EU WC

15 KDMF

8 NDC API

16 Listed Suppliers

$ API Reference Price

DEVELOPMENTS

23 Drugs in Development

INTERMEDIATES

1 Intermediate Suppliers

FINISHED DOSAGE FORMULATIONS

135 FDF Dossiers

27 FDA Orange Book

59 Europe

9 Canada

26 Australia

6 South Africa

8 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

TABLET;ORAL - 125MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

TABLET;ORAL - 250MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

TABLET;ORAL - 500MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

RELATED EXCIPIENT COMPANIES

1 Minakem

2 SPI Pharma

12 DKSH

5 Boai NKY Pharmaceuticals Ltd

6 Gangwal Healthcare

5 Nanjing Well Pharmaceutical

1 Shanghai Minbiotech

2 Kirsch Pharma

1 ACG Worldwide

5 Actylis

1 Alcedo Pharmachem

9 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd

3 Ashland

28 BASF

1 Clariant

10 Corel Pharma Chem

7 DFE Pharma

2 Esteem Industries

1 Finar

12 Gangwal Chemicals

4 Ideal Cures

2 Ingredion Pharma Solutions

24 Kerry

3 Keval Exports

3 Kima Chemical

6 Lonza Capsugel

15 Microlex e.U

2 Nanjing Bold Chemical

3 Nitika Pharmaceutical Specialities

2 Nomisma Healthcare

3 Novo Excipients

5 Pharmatrans-Sanaq

4 Pluviaendo

4 Prachin Chemical

1 Qianhao Chemical (Hebei) Co., Ltd

1 Qualicaps

15 Roquette

12 Seppic

4 Shanghai Shenmei Pharmaceutical Technology Co., Ltd

10 Sigachi Industries

4 Silverline Chemicals

2 The Dow Chemical Company

1 Ulanqab Kema New Material

4 Vasa Pharmachem

EXCIPIENTS BY APPLICATIONS

52 Fillers, Diluents & Binders

43 Coating Systems & Additives

38 Disintegrants & Superdisintegrants

TABLET;ORAL - 125MG Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

TABLET;ORAL - 250MG Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

TABLET;ORAL - 500MG Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons